Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich Sells 7,879 Shares

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich sold 7,879 shares of the company’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $44.21, for a total value of $348,330.59. Following the sale, the chief operating officer now owns 18,672 shares of the company’s stock, valued at $825,489.12. This trade represents a 29.67 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Peter Radovich also recently made the following trade(s):

• On Monday, February 3rd, Peter Radovich sold 2,627 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $48.22, for a total value of $126,673.94.
• On Friday, January 24th, Peter Radovich sold 3,177 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $47.92, for a total value of $152,241.84.
• On Tuesday, January 7th, Peter Radovich sold 1,998 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $42.82, for a total value of $85,554.36.

Mirum Pharmaceuticals Stock Up 1.6 %

Shares of NASDAQ MIRM opened at $47.87 on Friday. Mirum Pharmaceuticals, Inc. has a one year low of $23.14 and a one year high of $54.23. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. The business’s fifty day moving average price is $47.77 and its 200-day moving average price is $43.65. The stock has a market capitalization of $2.35 billion, a PE ratio of -23.70 and a beta of 1.04.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The firm had revenue of $99.41 million for the quarter, compared to analysts’ expectations of $96.64 million. On average, equities research analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. HC Wainwright upped their price target on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Robert W. Baird upped their price objective on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an “outperform” rating in a research note on Thursday, February 27th. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $58.20.

Institutional Trading of Mirum Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. Summit Investment Advisors Inc. lifted its holdings in Mirum Pharmaceuticals by 8.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 4,155 shares of the company’s stock worth $172,000 after purchasing an additional 312 shares in the last quarter. Jones Financial Companies Lllp lifted its holdings in Mirum Pharmaceuticals by 100.0% during the 4th quarter. Jones Financial Companies Lllp now owns 714 shares of the company’s stock worth $30,000 after purchasing an additional 357 shares in the last quarter. Schonfeld Strategic Advisors LLC lifted its holdings in Mirum Pharmaceuticals by 2.9% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 17,200 shares of the company’s stock worth $711,000 after purchasing an additional 487 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Mirum Pharmaceuticals during the 4th quarter worth about $35,000. Finally, Legato Capital Management LLC lifted its holdings in Mirum Pharmaceuticals by 7.9% during the 4th quarter. Legato Capital Management LLC now owns 13,395 shares of the company’s stock worth $554,000 after purchasing an additional 977 shares in the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.